50028
document
A randomized study on hormone-resistant prostatic cancer : estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate . A Norwegian multicenter study . A prospective randomized study has been carried out in order to compare three different treatment modalities for symptomatic metastatic hormone-resistant prostatic cancer . A total of 79 patients were included . One group was treated with estramustine phosphate , another with Epirubicin plus Medroxyprogesterone acetate ( MPA ) , while the third arm consisted of Epirubicin plus placebo . Best palliation was obtained by the combination of Epirubicin and MPA . This combination also seemed to be associated with the longest response duration .
50029
Intervention_Pharmacological
estramustine phosphate
50030
Intervention_Pharmacological
low dose epirubicin with or without medroxyprogesterone acetate
50031
Intervention_Pharmacological
estramustine phosphate
50032
Intervention_Pharmacological
Epirubicin plus Medroxyprogesterone acetate ( MPA )
50033
Intervention_Pharmacological
Epirubicin
50034
Intervention_Control
placebo
50035
Intervention_Pharmacological
Epirubicin and MPA
50036
Outcome_Physical
Best palliation
50037
Participant_Condition
total of 79 patients were included .